Sugi Predict

Sugi Predict / Compounds / SCHEMBL25075213

SCHEMBL25075213

SCHEMBL25075213

Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCC(C(=O)O)CC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 20/20 0.78
▸ LCK P06239 5/20 0.78
▸ LYN P07948 4/20 0.78
▸ NUDT14 O95848 2/20 0.72
▸ NUDT5 Q9UKK9 2/20 0.72
▸ EGFR P00533 6/20 0.72
▸ ITK Q08881 4/20 0.72
▸ TEC P42680 4/20 0.72
▸ BMX P51813 4/20 0.72
▸ SRC P12931 3/20 0.72
▸ ABL1 P00519 2/20 0.72
▸ ERBB2 P04626 2/20 0.72
▸ FYN P06241 2/20 0.72
▸ YES1 P07947 2/20 0.72
▸ HCK P08631 2/20 0.72
▸ FGR P09769 2/20 0.72
▸ FER P16591 2/20 0.72
▸ CSK P41240 2/20 0.72
▸ BLK P51451 2/20 0.72
▸ JAK3 P52333 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30144690 1.00 BTK (0.78) BTKLCKLYNNUDT14NUDT5
SCHEMBL30144783 0.91 BTK (0.72) BTKLCKLYNNUDT14NUDT5
SCHEMBL25075212 0.91 BTK (0.72) BTKLCKLYNNUDT14NUDT5
SCHEMBL22720793 0.89 BTK (0.75) BTKLCKLYNNUDT14NUDT5
SCHEMBL22243244 0.89 BTK (0.82) BTKLCKLYNNUDT14NUDT5
SCHEMBL22243281 0.89 BTK (0.82) BTKLCKLYNNUDT14NUDT5
SCHEMBL7001715 0.89 BTK (0.82) BTKLCKLYNNUDT14NUDT5
SCHEMBL29441896 0.89 BTK (0.82) BTKLCKLYNNUDT14NUDT5
SCHEMBL15915382 0.88 BTK (0.84) BTKLCKLYNNUDT14NUDT5
SCHEMBL2631407 0.88 BTK (0.84) BTKLCKLYNNUDT14NUDT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12139492-B2 Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase ENDOTARGET INC. 2024-11-12 — — US disclosed
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 — — US disclosed
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 — — US disclosed
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 — — US disclosed
WO-2023023537-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12139492-B2 Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase BTK, BCL6B, BCL9 BTK 1/4885LCK 10/4885LYN 7/4885
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN BTK 1/4885LCK 20/4885LYN 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback